AU1828399A - Novel formulations for the transdermal administration of asimadoline - Google Patents

Novel formulations for the transdermal administration of asimadoline

Info

Publication number
AU1828399A
AU1828399A AU18283/99A AU1828399A AU1828399A AU 1828399 A AU1828399 A AU 1828399A AU 18283/99 A AU18283/99 A AU 18283/99A AU 1828399 A AU1828399 A AU 1828399A AU 1828399 A AU1828399 A AU 1828399A
Authority
AU
Australia
Prior art keywords
asimadoline
transdermal administration
novel formulations
formulations
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU18283/99A
Inventor
William Van Osdol
Tyler Watanabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of AU1828399A publication Critical patent/AU1828399A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU18283/99A 1997-12-22 1998-12-15 Novel formulations for the transdermal administration of asimadoline Abandoned AU1828399A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6837697P 1997-12-22 1997-12-22
US60068376 1997-12-22
PCT/US1998/026652 WO1999032096A1 (en) 1997-12-22 1998-12-15 Novel formulations for the transdermal administration of asimadoline

Publications (1)

Publication Number Publication Date
AU1828399A true AU1828399A (en) 1999-07-12

Family

ID=22082169

Family Applications (1)

Application Number Title Priority Date Filing Date
AU18283/99A Abandoned AU1828399A (en) 1997-12-22 1998-12-15 Novel formulations for the transdermal administration of asimadoline

Country Status (2)

Country Link
AU (1) AU1828399A (en)
WO (1) WO1999032096A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3932390A1 (en) 2020-07-02 2022-01-05 Dr. August Wolff GmbH & Co. KG Arzneimittel Topical gel formulation containing asimadoline

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19531464A1 (en) * 1995-08-26 1997-02-27 Merck Patent Gmbh N-methyl-N - [(1S -) - 1-phenyl-2 - ((3S) -3-hydroxypyrrolidin 1-yl -) - ethyl] -2,2-diphenyl-acetamide
US5763445A (en) * 1996-03-08 1998-06-09 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
JP2001506652A (en) * 1996-12-16 2001-05-22 アルコン ラボラトリーズ，インコーポレイテッド Topical use of kappa opioid agonist to treat eye pain

Also Published As

Publication number Publication date
WO1999032096A1 (en) 1999-07-01

Similar Documents

Publication Publication Date Title
AU6513298A (en) Therapeutic compositions
AU6740298A (en) Pharmaceutical composition
AU5136998A (en) Medicinal composition
AU7964398A (en) Dental formulation
AU1887401A (en) Medicinal composition
AU8107998A (en) Pharmaceutical compositions
AU8591898A (en) Pharmaceutical compounds
AU7904998A (en) Pharmaceutical composition containing peptichemio
AU9343098A (en) Pharmaceutical composition
AU732214C (en) Biphenyl derivatives and drug composition
AU5494298A (en) Pharmaceutical compositions for the treatment of the eye
AU5210298A (en) Methods for the preparation of benzophenone derivatives
AU3459697A (en) Novel pyrimidine compounds and drug compositions
AU1828399A (en) Novel formulations for the transdermal administration of asimadoline
AU8102498A (en) Preparation of diaryl-benzopyrans
AU7641098A (en) Therapeutic composition
AU1772499A (en) Preparation of isopulegol
AU5182099A (en) Pharmaceutical formulation
AU9007598A (en) Process for the preparation of carvone
AU6782298A (en) Fibrocyte-based cellular therapy formulations
AU6734698A (en) Pharmaceutical composition for the programmed release of dexfenfluramine
AU7022600A (en) Initiation of oestrus
AU6067298A (en) Pharmaceutical formulation
AUPO597997A0 (en) Medicinal composition
AUPO840697A0 (en) Therapeutic compositions

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase